Patient Sarah-Beth

A Clear Difference

>50% of patients achieved clear or almost clear skin* by week 8

(53.8% vs 15.1% and 51.3% vs 7.6% vehicle†; P<0.0001)1,2

SEE RESULTS
Patient Isabelle

Meaningful Itch Relief

>50% of patients achieved Itch NRS4‡ by week 8

(52.2% vs 15.4% and 50.7% vs 16.3% vehicle†; P<0.0001)1,2

PROVIDE ITCH RELIEF
Patient Alex

Onset of Itch Reduction

Itch NRS4 response seen as early as day 3

(18.4% vs 4.2% and 13.2% vs 0% vehicle†)3

VIEW DATA
Patient Henry

Significant EASI Improvement

>60% of patients achieved EASI-75§ by week 8

(62.1% vs 24.6% and 61.8% vs 14.4% vehicle†; P<0.0001)2

DELIVER IMPROVEMENT
Patient Faith

Safety and Adverse Event Results

Learn more about the safety data from the clinical trials

SEE ADVERSE EVENTS PROFILE

OPZELURA was studied in 2 identically designed, double-blind, randomized, vehicle-controlled trials (TRuE-AD1 and TRuE-AD2). The 2 studies included 1249 adult and pediatric patients ≥12 years of age with an affected BSA of 3%-20% and an IGA score of 2 or 3 on a severity scale of 0-4. Patients were randomized to monotherapy with OPZELURA, ruxolitinib cream 0.75%, or vehicle twice daily for 8 weeks1,2

*Measured by IGA-TS, defined as the achievement of clear (IGA 0) or almost clear (IGA 1) skin with at least a 2-point improvement from baseline.1

†In TRuE-AD1 and TRuE-AD2, respectively.1,2

‡Itch NRS4 is defined as the achievement of at least a 4-point improvement in daily itch on a 0- to 10-point scale, considered a clinically meaningful response; patients in the analysis had an NRS score ≥4 at baseline.1,2

§EASI-75 is defined as the achievement of at least 75% improvement in EASI score from baseline.2

BSA=body surface area; EASI=Eczema Area and Severity Index; IGA=Investigator's Global Assessment; IGA-TS=Investigator's Global Assessment Treatment Success; JAK=Janus kinase; NRS=numeric rating scale.

References: 1. Opzelura. Prescribing Information. Incyte Corporation; 2022. 2. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863-872. doi:10.1016/j.jaad.2021.04.085. 3. Data on file. Incyte Corporation. 2021.